The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Novel coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development

  • Lowest Price Guaranteed From USD 4,899

  • Published
    April 2020

  • Pages
    122

  • View Count
    10248

Example Insights

  1. More than 50 therapeutic entities / vaccines are currently under development by prominent players for the treatment / prevention of COVID-19. In fact, more than 100 clinical trials have been registered till date.
  2. The players have adopted multiple approaches for the development of vaccines. Some of the approaches adopted by the companies include, whole virus vaccines, subunit vaccines, and nucleic acid based vaccines. 
  3. Around 50% of the interventional clinical trials are being conducted in China. In addition, a number of trials have recently been initiated in the US and several European countries. 
  4. We were able to identify close to 250 diagnostic tests approved / under development for the diagnosis of COVID-19. Majority of these tests are based on RT-PCR.
  5. Over 60% of the diagnostic tests are being developed by companies based in the Asia-Pacific. In the recent days, a number of diagnostic tests have been developed by players based in the Europe, as well.
  6. We conducted a detailed grant analysis on over 1,000 academic grants that have been awarded for research on coronavirus, till date. Based on the analysis, we were able to identify multiple leading research institutes that have received NIH grants for research on coronavirus. Some of the leading academic institutes include, University of North Carolina, University of Iowa, University of Pennsylvania, University of Texas and University of Colorado.

Overview

[COVID-19 SERIES] New coronavirus (COVID-19) is a previously unidentified strain of coronavirus, that first emerged in the Chinese city of Wuhan in December 2019. The virus belongs to the same family as the virus that causes severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). On 30th January 2020, the World Health Organization (WHO) declared the coronavirus outbreak as a global health emergency. In fact, the virus is estimated to have infected more than 45,000 individuals, around the globe (estimates till the second week of February 2020). In order to deal with this outbreak and prevent the spread of virus to new geographies, countries are adopting various precautions. 

The WHO has recently released the Strategic Preparedness and Response Plan (SPRP) that lays out activities and resources needed by international health organizations globally, including WHO, to implement priority public health measures in support of countries to prepare and respond to COVID-19 for a period between February to April 2020.

More than 35 pharmaceutical / biotechnology companies, government agencies, and research institutes have disclosed research programs focused on developing vaccines / drugs to prevent or treat COVID-19 infections. In addition, close to 250 diagnostic tests are currently available / being developed for effective diagnosis of patients. The rising healthcare burden of the disease has also attracted significant funding to fuel drug development efforts in this space; recent funding initiatives include USD 100 million funding by Bill & Melinda Gates Foundation, and USD 26 million vaccine development fund by the UK government.

Scope of the Report

The “Novel coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development” report features an extensive study of the vaccine / drug candidates and diagnostic tests being investigated for COVID-19 infection prevention, treatment and diagnosis. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of vaccines and drugs being developed for the prevention and treatment of COVID-19 infection, providing information on the developer(s), phase of development (clinical, preclinical, discovery) of product candidates, type of molecule (vaccines, antibodies, small molecules, others), mechanism of action.
  • A detailed clinical trial analysis of completed, ongoing and planned studies of candidates being evaluated for the treatment of COVID-19, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration date, enrolled patient population and regional distribution of trials, type of drug being evaluated, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), study focus, and clinical endpoints.
  • A detailed assessment of the diagnostic tests being developed for the diagnosis of COVID-19 infection, providing information on test developer(s), development geography, technology being used in the test, type of test and test purpose.
  • An analysis depicting the prevalent and emerging trends related to this domain as represented on the social media platform, Twitter. In addition to providing information on day-on-day trends related to the volume of tweets, the analysis highlights the most frequently talked about areas, active players, and influential authors.
  • An in-depth analysis of more than 2,100 grants that have been awarded to research institutes engaged in projects related to coronavirus, highlighting various important parameters associated with grants, such as year of award, support period, amount awarded, funding institute, administration institute center, funding institute center, funding mechanism, spending categorization, grant type, responsible study section, focus area, type of recipient organization and prominent program officers. It also features a detailed 2X2 plot comparing the key opinion leaders based on parameters, such as amount awarded and number of awarded grants. 
  • An analysis of the investments made across different companies/ academic institutes driving development efforts in this space. The analysis specifically highlights the key investors involved in this space.

Elaborate profiles of the key players involved in vaccine / drug and diagnostic development. Each profile features a brief overview of the company, information on its development programs, details related to funding, and collaborations related to COVID-19.

Contents

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY
2.1. Chapter Overview
2.2. COVID-19: List of Drugs and Vaccines Developers
2.3. Key Developers
2.3.1. AbbVie
2.3.2. AbCellera / Eli Lilly
2.3.3. Ascletis Pharmaceuticals
2.3.4. Baylor College of Medicine
2.3.5. BenevolentAI
2.3.6. Biocryst Pharma
2.3.7. BioNTech / Pfizer
2.3.8. CIPLA
2.3.9. Clover Biopharmaceuticals / GSK
2.3.10. CureVac
2.3.11. CytoDyn
2.3.12. Deragen / Dankook University / Emory University
2.3.13. EastGate Biotech
2.3.14. GeoVax / BravoVax
2.3.15. Gilead Sciences
2.3.16. Heat Biologics
2.3.17. Imperial College London
2.3.18. Inovio Pharmaceuticals
2.3.19. InSilico Medicne
2.3.20. Jenner Institute
2.3.21. Johnson and Johnson
2.3.22. Moderna Therapeutics
2.3.23. NanoViricides
2.3.24. Novavax
2.3.25. Regeneron Pharmaceuticals
2.3.26. Regeneron Pharmaceuticals / Sanofi
2.3.27. ShanghaiTech University
2.3.28. Sirnaomics
2.3.29. Tongji University / Stemirna Therapeutics
2.3.30. University of Queensland
2.3.31. Vaxart
2.3.32. Vir Biotechnology
2.3.33. Vir Biotechnology / Alnylam Pharmaceuticals
2.3.34. Takeda

2.4. COVID-19 Pipeline: Analysis
2.4.1. COVID-19 Pipeline: Analysis by Location of Headquarters
2.4.2. COVID-19 Pipeline: Analysis by Type of Candidate
2.4.3. COVID-19 Pipeline: Analysis by Type of Candidate and Drug Development Approach
2.4.4. COVID-19 Pipeline: Analysis by Development Status
2.4.5. COVID-19 Pipeline: Analysis by Type of Drug Class

3. COVID-19: DIAGNOSTICS CURRENT MARKET LANDSCAPE
3.1. Chapter Overview
3.2. COVID-19: List of Diagnostic Developers
3.2.1. COVID-19 Diagnostic Tests: Analysis by Developer Headquarters
3.2.2. COVID-19 Diagnostic Tests: Analysis by Test Application
3.2.3. COVID-19 Diagnostic Tests: Analysis by Development Status
3.2.4. COVID-19 Diagnostic Tests: Analysis by Type of Assay
3.2.5. COVID-19 Diagnostic Tests: Analysis by Type of Technique
3.2.6. COVID-19 Diagnostic Tests: Analysis by Regulatory Compliance

4. FUNDING AND INVESTMENT ANALYSIS
4.1. Chapter Overview
4.2. COVID-19: List of Funding Instances
4.2.1. COVID-19: Analysis by Cumulative Number of Instances
4.2.2. COVID-19: Analysis by Cumulative Amount Invested
4.2.3. COVID-19: Analysis by Purpose of Funding

5. ACADEMIC GRANTS ANALYSIS
5.1. Chapter Overview
5.2. Scope and Methodology
5.3. COVID-19: Academic Grant Analysis
5.3.1. Analysis by Year of Award
5.3.2. Analysis by Amount Awarded
5.3.3. Analysis by Administering Institute Center
5.3.4. Analysis by Support Period
5.3.5. Analysis by Funding Institute Center and Support Period
5.3.6. Analysis by Funding Mechanism
5.3.7. Analysis by Type of Grant Application
5.3.8. Popular NIH Departments
5.3.9. Analysis by Type of Recipient Organization
5.3.10. Popular Recipient Organizations
5.3.11. Analysis By Grant Mechanism
5.3.12. Prominent Program Officers
5.3.13. Regional Distribution of Recipient Organization

6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. COVID-19: List of Interventional Trials
6.3.1. Analysis by Trial Status
6.3.2. Analysis by Trial Phase
6.3.3. Analysis by Study Design
6.3.4. Analysis by Type of Sponsor / Collaborator
6.3.5. Geographical Analysis by Number of Clinical Trials
6.3.6. Geographical Analysis by Enrolled Patient Population
6.4. COVID-19: List of Observational Trials

7. SOCIAL MEDIA ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Corona Virus: Trends on Twitter
7.3.1. Cumulative Week-wise Activity by Volume of Tweets
7.3.2. Historical Trends in Volume of Tweets
7.3.3. Trending Words / Phrases on Twitter
7.3.4. Most Prolific Contributors on Twitter

7.4. Prevalent Trends Related to Coronavirus
7.4.1. Ongoing Developments
7.4.2. Key Historical Trends
7.4.3. Geographical Activity
7.5. Concluding Remarks

8. RECENT UPDATES
8.1. Chapter Overview
8.2. Therapeutics and Vaccines Development
8.3. Funding
8.4. Diagnostics

9 APPENDIX 1: TABULATED DATA

10 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 COVID-19 Therapeutics / Vaccines Pipeline: Distribution by Developer Headquarters
Figure 2.2 COVID-19 Therapeutics / Vaccines Pipeline: Distribution by Type of Candidate
Figure 2.3 COVID-19 Therapeutics / Vaccines Pipeline: Distribution by Drug Development Approach
Figure 2.4 COVID-19 Therapeutics / Vaccines Pipeline: Distribution by Phase of Development
Figure 2.5 COVID-19 Therapeutics Pipeline: Distribution by Type of Drug Class
Figure 2.6 COVID-19 Therapeutics Vaccines Pipeline: Distribution by Type of Drug Class
Figure 3.1 COVID-19 Diagnostics Tests: Distribution by Developer Headquarters
Figure 3.2 COVID-19 Diagnostics Tests: Distribution by Test Application
Figure 3.3 COVID-19 Diagnostics Tests: Distribution by Development Status
Figure 3.4 COVID-19 Diagnostic Tests: Distribution by Type of Test
Figure 3.5 COVID-19 Diagnostic Tests: Distribution by Test Specifications
Figure 3.6 COVID-19 Diagnostic Tests: Distribution by Regulatory Compliance
Figure 4.1 Funding and Investment Analysis: Cumulative Number of Funding Instances
Figure 4.2 Funding and Investment Analysis: Cumulative Amount Invested,  (USD Million)
Figure 4.3 Funding and Investment Analysis: Distribution by Purpose of Funding
Figure 4.4 Funding and Investment Analysis: Most Active Investors
Figure 5.1 Grant Analysis: Cumulative Trend by Year of Projects
Figure 5.2 Grant Analysis: Cumulative Trend by Amount Awarded 
(USD Million) 
Figure 5.3 Grant Analysis: Distribution by Administering Institute Center
Figure 5.4 Grant Analysis: Distribution by Support Period
Figure 5.5 Grant Analysis: Distribution by Funding Institute Center and Support Period
Figure 5.6 Grant Analysis: Distribution by Funding Mechanism
Figure 5.7 Grant Analysis: Distribution by Type of Grant Application
Figure 5.8 Grant Analysis: Popular NIH Departments
Figure 5.9 Grant Analysis: Type of Recipient Organization
Figure 5.10 Grant Analysis: Popular Recipient Organizations
Figure 5.11 Grant Analysis: Popular Grant Mechanism
Figure 5.12 Grant Analysis: Prominent Program Officers
Figure 5.13 Top Program Officers: Distribution by Number of Grants and Amount Awarded
Figure 5.14 Grant Analysis: Regional Distribution of Recipient Organization
Figure 6.1 Clinical Trial Analysis: Distribution by Trial Status
Figure 6.2 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.3 Clinical Trial Analysis: Distribution of Patient Enrollment and Trial Phase
Figure 6.4 Clinical Trial Analysis: Distribution by Study Design
Figure 6.5 Clinical Trial Analysis: Top Sponsors
Figure 6.6 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Figure 6.7 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 7.1 Social Media Analysis: Cumulative Year-Wise Activity by Volume of Tweets
Figure 7.2 Social Media Analysis: Historical Trends on Twitter
Figure 7.3 Social Media Analysis: Trending Words / Phrases on Twitter
Figure 7.4 Social Media Analysis: Most Prolific Contributors on Twitter
Figure 7.5 Ongoing Developments: Google News
Figure 7.6 Historical Timeline: Analysis of Google Trends
Figure 7.7 Geographical Activity: Analysis of Google Trend

List Of Tables

Table 2.1 COVID-19: List of Drugs and Vaccine Developers 
Table 2.2 COVID-19 Clinical Trials: lopinavir
Table 2.3 COVID-19 Clinical Trials: remdesivir
Table 2.4 COVID-19: List of Recently Identified Therapeutics / Vaccines
Table 3.1 COVID-19: List of Diagnostics Tests
Table 3.2 COVID-19: Details of Diagnostics Tests
Table 4.1 COVID-19: List of Funding and Investments
Table 6.1 COVID-19: List of Interventional Trials
Table 6.2 COVID-19: List of Sponsors
Table 6.3 COVID-19: List of Observational Trials
Table 9.1 COVID-19 Therapeutics / Vaccine Pipeline: Distribution by Developers Headquarter
Table 9.2 COVID-19 Therapeutics / Vaccine Pipeline: Distribution by Type of Candidate
Table 9.3 COVID-19 Therapeutics / Vaccine Pipeline: Distribution by Drug Development Approach 
Table 9.4 COVID-19 Therapeutics / Vaccine Pipeline: Distribution by Phase of Development
Table 9.5 COVID-19 Therapeutics Pipeline: Distribution by Type of Drug Class
Table 9.6 COVID-19 Therapeutics / Vaccine Pipeline: Distribution by Type of Vaccine 
Table 9.7 COVID-19 Diagnostics Tests: Distribution by Developer Headquarters
Table 9.8 COVID-19 Diagnostics Tests: Distribution by Test Application
Table 9.9 COVID-19 Diagnostics Tests: Distribution by Development Status
Table 9.10 COVID-19 Diagnostics Tests: Distribution by Type of Test
Table 9.11 COVID-19 Diagnostics Tests: Distribution by Test Specifications
Table 9.12 COVID-19 Diagnostics Tests: Distribution by Regulatory Compliance
Table 9.13 COVID-19 Funding and Investment Analysis: Cumulative Number of Instances
Table 9.14 COVID-19 Funding and Investment Analysis: Cumulative Amount Invested, (USD Million)
Table 9.15 COVID-19 Funding and Investment Analysis: Distribution by Purpose of Funding
Table 9.16 COVID-19 Funding and Investment Analysis: Most Active Investors
Table 9.17 Grant Analysis: Cumulative Trend by Year of Projects
Table 9.18 Grant Analysis: Trend by Amount Awarded (USD Million)
Table 9.19 Grant Analysis: Distribution by Administering Institute Center
Table 9.20 Grant Analysis: Distribution by Support Period
Table 9.21 Grant Analysis: Distribution by Funding Institute Center and Support Period
Table 9.22 Grant Analysis: Distribution by Funding Mechanism
Table 9.23 Grant Analysis: Distribution by Type of Grant Application
Table 9.24 Grant Analysis: Popular NIH Departments
Table 9.25 Grant Analysis: Type of Recipient Organization
Table 9.26 Grant Analysis: Popular Recipient Organization
Table 9.27 Grant Analysis: Popular Funding Mechanism
Table 9.28 Clinical Trial Analysis: Distribution by Trial Status
Table 9.29 Clinical Trial Analysis: Distribution by Trial Phase
Table 9.30 Clinical Trial Analysis: Distribution of Patient Enrollment and Trial Phase
Table 9.31 Clinical Trial Analysis: Top Sponsors
Table 9.32 Social Media Analysis: Cumulative Year-Wise Activity by Volume of Tweets

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. 1drop
  2. AB ANALITICA
  3. AbbVie
  4. AbCellera
  5. Absea Biotechnology
  6. Accelerate Technology
  7. ADT Biotech
  8. Affiliated Hospital to Academy of Military Medical Sciences
  9. AIM ImmunoTech
  10. Aldatu Biosciences
  11. Alibaba Group
  12. Alnylam Pharmaceuticals
  13. Altimmune
  14. altona Diagnostics
  15. AmonMed Biotechnology
  16. Amoy Diagnostics
  17. Ampligene India Biotech
  18. Anatolia Geneworks
  19. APEIRON Biologics
  20. Ariana Grande
  21. Asan Medical Center
  22. Ascletis Pharma
  23. Assistance Publique Hopitaux de Paris
  24. Atila BioSystems
  25. Ativa Medical
  26. Attomarker
  27. Baiya Phytopharm
  28. BARDA
  29. Bayer
  30. Baylor College of Medicine
  31. Beijing 302 Hospital
  32. Beijing Applied Biological Technologies
  33. Beijing CC-Pharming
  34. Beijing Chao Yang Hospital
  35. Beijing Genskey Medical Technology
  36. Beijing Infervision Technology
  37. Beijing Kewei Clinical Diagnostic Reagent
  38. Beijing Kinhawk Pharmaceutical
  39. Beijing Microread Genetics
  40. Beijing NaGene Diagnosis Reagent
  41. Beijing Shengkun Kangru Medical Equipment
  42. Beijing Staidson Biopharma
  43. Beijing Wantai Biological Pharmacy
  44. Beijing YouAn Hospital
  45. BenevolentAI
  46. Beroni Group
  47. BeyondSpring
  48. BGI Health
  49. Bill & Melinda Gates Foundation
  50. BioCryst Pharma
  51. BioFire Defense
  52. Biogen
  53. Biogen Foundation
  54. BioMedomics
  55. Biomeme
  56. bioMérieux
  57. BIONEER Corporation
  58. BioNTech
  59. BioXyTran
  60. BluSense Diagnostics
  61. Boditech
  62. BravoVax
  63. Canary Health Technologies
  64. Cancer Rop
  65. CanSino Biologics
  66. Capital Medical University
  67. CapitalBio Technology
  68. CAR-T (Shanghai) Biotechnology
  69. Caspr Biotech
  70. CellSafe
  71. Cellular Biomedicine Group
  72. Cel-SCI
  73. Celularity
  74. Center for Convergent Research of Emerging Virus Infection
  75. Centers for Disease Control and Prevention (CDC)
  76. Cepheid
  77. CerTest Biotec
  78. Chaozhou Hybribio Biochemistry
  79. China Academy of Chinese Medical Sciences
  80. ChinaGoAbroad
  81. Chinese Academy of Medical Sciences
  82. ChromaCode
  83. Chugai Pharmaceutical
  84. Cipla
  85. Clinical Trial Center North
  86. Clonit
  87. Clover Biopharmaceuticals
  88. Coalition for Epidemic Preparedness Innovations (CEPI)
  89. Cocrystal
  90. Codagenix
  91. Co-diagnostics
  92. Columbia University
  93. Coyote Bioscience
  94. CR2O
  95. Credo Diagnostics Biomedical
  96. CSL
  97. CTK Biotech
  98. CureVac
  99. CytoDyn
  100. DAAN Gene
  101. Dalhousie University
  102. Dankook University
  103. DART Diagnostics
  104. Department of Health, Generalitat de Catalunya
  105. Dergaen
  106. Diagnostics for the Real World
  107. DigiFuidic Biotech
  108. Distributed Bio
  109. DTwist
  110. dy Test
  111. Dynamiker Biotechnology
  112. EastGate Biotech
  113. Eli Lilly
  114. Emergency Diagnostic Research
  115. Emergent BioSolutions
  116. Emory University
  117. Enanta Pharmaceuticals
  118. Epitope Diagnostics
  119. Erasmus Medical Center
  120. Estee Lauder
  121. EUROIMMUN
  122. European Innovation Council (EIC)
  123. FABPulous
  124. FemtoDx
  125. Fifth Affiliated Hospital, Sun Yat-Sen University
  126. First Affiliated Hospital Bengbu Medical College
  127. First Affiliated Hospital of Chongqing Medical University
  128. First Affiliated Hospital of Fujian Medical University
  129. First Affiliated Hospital of Wenzhou Medical University
  130. First Affiliated Hospital of Xinjiang Medical University
  131. First Affiliated Hospital of Zhejiang University
  132. Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
  133. Fujifilm Holdings
  134. GenapSys
  135. GenBody
  136. Gencurix
  137. Gene Biosystems
  138. GeneFirst
  139. Genekam Biotechnology
  140. Geneodx (Sinopharm Group)
  141. General Biologicals Corporation
  142. GeneReach Biotechnology Corporation
  143. Generex Biotechnology
  144. Genesystem
  145. Genetic Signatures
  146. GenMark Diagnostics
  147. Genomica
  148. Genomictree
  149. GenScript
  150. GeoVax
  151. German Center for Infection Research
  152. Germans Trias i Pujol Hospital
  153. Getein Biotech
  154. Gilead Sciences
  155. GlaxoSmithKline
  156. Great Basin - Vela Operations
  157. Group 42 (G42)
  158. Guangdong Huayin Medicine Science
  159. Guangzhou 8th People's Hospital
  160. Guangzhou Blood Center
  161. Guangzhou Darui Biotechnology
  162. Guangzhou Fenghua Bioengineering
  163. GuangZhou HEAS BioTech
  164. Guangzhou Wondfo Biotech
  165. Hackensack Meridian Health
  166. Hangzhou AllTest Biotech
  167. Hangzhou Matridx Biotechnology
  168. Heat Biologics
  169. Henan Provincial People's Hospital
  170. Hibergene
  171. Hospital Authority, Hong Kong
  172. Huada Biotechnology
  173. Huangshi Central Hospital
  174. Hubei Hospital of Traditional Chinese Medicine
  175. Hudson Medical
  176. Huilan Zhang
  177. Humasis
  178. Huwel Lifesciences
  179. iBio
  180. ICBFM
  181. IDbyDNA
  182. IDT Biologika
  183. ImmunoPrecise Antibodies
  184. Impact BioMedical
  185. Imperial College London
  186. Incyte
  187. InflaRx
  188. Innovation Pharmaceuticals
  189. Innovative Medicines Initiative
  190. Innovative Precision Medicine Group
  191. Innovita Biological Technology
  192. Inovio Pharmaceuticals
  193. InSilico Medicine
  194. Institute of Medicine and Biotechnology, Chinese Academy of Medical Sciences
  195. Intec Products
  196. Janssen Pharmaceuticals
  197. Jenner Institute
  198. Jiangsu Bioperfectus Technologies
  199. Jiangsu Qitian Gene Biotechnology
  200. Jiangxi Qingfeng Pharmaceutical
  201. Jieming QU
  202. Jingmen No.1 Peoples Hospital
  203. JN Medsys
  204. Johns Hopkins
  205. Johnson and Johnson
  206. Kamada
  207. Kansas State University Research Foundation
  208. Kephera Diagnostics
  209. Kering Group 
  210. KH Medical
  211. KogeneBiotech
  212. LabGenomics
  213. Lexagene
  214. Liferiver Bio-tech (Shanghai ZJ Bio-Tech)
  215. Lihir Medical Centre
  216. Liming Bio-Products
  217. LineaRx (Applied DNA Sciences)
  218. L'Oreal
  219. Luminex
  220. Luminostics
  221. LVMH Group
  222. Mabsky Bio-Tech
  223. Mammoth Biosciences
  224. Mannin Research
  225. Mariah Carey
  226. Massachusetts General Hospital
  227. Mastercard Impact Fund
  228. McMaster University
  229. Medicago
  230. Medical Innovation Ventures
  231. MedicalSystem Biotechnology
  232. Mesoblast
  233. MiCo Biomed
  234. Mikrogen
  235. Mobidiag
  236. Moderna Therapeutics
  237. Molbio Diagnostics
  238. Mylab Discovery Solutions
  239. Nanjing Vazyme Medical Technology
  240. NanoBio Lab
  241. Nanotech
  242. NanoViricides
  243. Nantong Egens Biotechnology
  244. Nanyang Central Hospital
  245. National Institute for Control of Vaccines and Biologicals
  246. National Institute of Allergy and Infectious Diseases (NIAID)
  247. Niguarda Hospital
  248. Ningbo Health Gene Technologies
  249. No.2 People's Hospital of Fuyang City
  250. Norgen Biotek
  251. Novacyt
  252. Novavax
  253. Novimmune
  254. OPTOLANE Technologies
  255. Oxford Nanopore
  256. OyaGen
  257. PaxGen Bio
  258. Peking Union Medical College Hospital
  259. PerkinElmer
  260. Pfizer
  261. Pharmstandard
  262. Phillipine Genome Center
  263. Pinpoint Science
  264. Promis Diagnostics
  265. Puren Hospital Affiliated to Wuhan University of Science and Technology
  266. Q Biomed
  267. QIAGEN
  268. Qilu Hospital of Shandong University
  269. Qingdao Jianma Gene Technology
  270. QuantuMDx
  271. RainSure Bio
  272. Rajavithi Hospital
  273. Randox Laboratories
  274. R-Biopharm
  275. RedHill Biopharma
  276. Regeneron Pharmaceuticals
  277. Renmin Hospital of Wuhan University
  278. Roche (Genentech)
  279. Roche Molecular Diagnostics
  280. Ruijin Hospital
  281. Sanofi
  282. Sansure Biotech
  283. SD BIOSENSOR
  284. Second Affiliated Hospital of Wenzhou Medical University
  285. Second Affiliated Hospital of Xi'an Jiaotong University
  286. Seegene
  287. Selfdiagnostics Deutschland
  288. Sentinel
  289. Serum Institute of India
  290. Servoprax
  291. Shaanxi Lifegen
  292. Shanghai Fosun Long March Medical Science
  293. Shanghai GeneoDx Biotechnology
  294. Shanghai Hengrui Pharmaceutical
  295. Shanghai Kehua Bio-engineering
  296. Shanghai Public Health Clinical Center
  297. Shanghai ZJ Bio-Tech
  298. ShanghaiTech University
  299. Shenyang Pharmaceutical University
  300. Shenyang Tonglian Group
  301. Shenzhen Bioeasy Biotechnology
  302. Shenzhen Geno-Immune Medical Institute
  303. Shenzhen Second People's Hospital
  304. Shenzhen Tailored Medical
  305. Shenzhen Third People's Hospital
  306. Shenzhen Yhlo Biotech
  307. Shiseido 
  308. ShuGuang Hospital
  309. Singapore Government
  310. Sirnaomics
  311. Snibe
  312. Sona Nanotech
  313. Sorrento Therapeutics
  314. South Korea Government
  315. Southeast University, China
  316. St. Petersburg Research Institute of Vaccines and Sera
  317. Stemirna
  318. Stilla Technologies
  319. Sugentech
  320. SunStar Joint Stock Company
  321. Swarovski 
  322. Taizhou ZECEN Biotech
  323. Takeda
  324. Takis Biotech
  325. Tang-Du Hospital
  326. Tasly Pharmaceuticals
  327. TCM Biosciences
  328. Tencent
  329. The Fifth Medical Center of Chinese PLA General Hospital
  330. The First Affiliated Hospital of Guangzhou Medical University
  331. The Ninth Hospital of Nanchang
  332. The Second Affiliated Hospital of Harbin Medical University
  333. The Second Hospital of Nanjing Medical University
  334. The sixth people's hospital of Shenyang
  335. The University of Hong Kong
  336. The University of Queensland
  337. Thermo Fisher Scientific
  338. Tianhe Stem Cell Biotechnologies
  339. Tianjin Haihe Hospital
  340. Tianjin University
  341. Tib Molbiol
  342. Tiziana Life Sciences
  343. Tongji Hospital
  344. Tongji University
  345. Tonix Pharmaceuticals
  346. Tuohua Biological Technology
  347. Twist Bioscience
  348. U.S. Army Medical Research and Development Command
  349. UK Government
  350. University of Alberta
  351. University of California
  352. University of Cincinnati
  353. University of Hong Kong
  354. University of Macau
  355. University of Minnesota
  356. University of Oxford
  357. University of Queensland
  358. University of Washington
  359. US Centers for Disease Control and Prevention
  360. Vancouver Coastal Health
  361. Vaxart
  362. Vcanbio Cell & Gene Engineering
  363. Veredus Laboratories
  364. Vir Biotechnology
  365. Vircell
  366. VivaChek Biotech
  367. WanBangDe Pharmaceutical Group
  368. Wellcome
  369. Wenzhou Central Hospital
  370. West China Hospital
  371. World Health Organization (WHO)
  372. Wuhan Benevolent General Association
  373. Wuhan Easydiagnosis Biomedicine
  374. Wuhan Hamilton Bio-technology
  375. Wuhan Huoshenshan Hospital
  376. Wuhan Jinyintan Hospital
  377. Wuhan Red Cross
  378. Wuhan Union Hospital
  379. WuXi Biologics
  380. Xi’an Tianlong Science and Technology
  381. Xiamen Biotime Biotechnology
  382. Xiamen Zeesan Biotech
  383. Xijing Hospital
  384. Xinxiang medical university
  385. Zalgen Labs
  386. Zhejiang Hisun Pharmaceutical
  387. Zhengzhou Humanwell Biocell Biotechnology
  388. ZhiYong Peng
  389. Zhongda Hospital
  390. Zhongnan Hospital
  391. Zhuhai Haitai Biological Pharmaceutical

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com